Pictet Biotech I dy GBP
ISIN: LU0448836352 | MEX: T3AAAB | CITI: GLJ4
-
Buy 75,681 GBX
-
Sell 75,681 GBX
-
Price Change 1.79700%
Past Performance
- 2nd May 2020 to 2nd May 20218.68%
- 2nd May 2021 to 2nd May 2022-22.86%
- 2nd May 2022 to 2nd May 202316.09%
- 2nd May 2023 to 2nd May 20248.84%
- 2nd May 2024 to 2nd May 2025-8.08%
Objectives and Approach
To increase the value of your investment while seeking to achieve a positive social impact. Reference Index MSCI AC World (USD), an index that does not take into account environmental, social and governance (ESG) factors. Used for risk monitoring, performance objective and performance measurement.
Key Information
Inception | 30th Nov 1995 |
Historic Yield | 0% |
Sector | IA Specialist |
Fund Size | £1185.451mn |
Fund Type | SICV |
Classification | Income |
Charges
Total Ongoing Charges
Please note that whilst we endeavour to show all charges associated with specific funds, sometimes this is not possible due to the information not being made available by the fund provider. In such cases transaction or incidental cost information may be missing. |
1.2454% |
Initial Charge | 0% |
AMC | 0.80% |
Our Platform Charge We charge a platform fee of 0.30%. Our charges are shown on our rates and charges sheet |
0.30% |
Cost and Charges Information
This calculator provides you with costs and charges information regarding our charges and, where relevant, the costs within this investment product
Account Type
Annual charges
These are the annual costs based on an initial investment amount of over 1 year assuming a net zero growth rate
Cost Category | % of Investment | lump sum costs |
---|---|---|
Our annual fee
Our annual feeIncludes our platform fee at 0.30% per annum (excluding Charles Stanley Multi Asset Funds and anycash held). The min fee is £60, the max is £600 per annum, plus SIPP administration fee (if applicable, only charged if < £30,000 held) – see here |
0.30% | |
Dealing charges
Dealing chargesAny one-off commission charges associated with investing. Note that government taxes and levies are not included. This does not include any commission credits you may have available |
N/A | |
Product provider costs
Product provider costsProduct provider costs shown are inclusive of the fund ongoing charges figure (OCF), transaction costs and incidental costs |
1.2454% | |
Total (£)
Total (£)Costs per annum displayed in monetary value |
||
Total (%)
Total (%)Costs per annum displayed as a percentage of investment value |
Cumulative effect of charges on your investment's return
This illustration assumes that costs occur evenly throughout the year, charges are paid out of the investment evenly throughout the year, and that an annual growth rate of applies evenly throughout the year, before any charges including product charges
lump sum invested with an assumed growth rate of | 1 year | years |
---|---|---|
What you might get back at with no charges applied
What you might get back at with no charges appliedThese are the illustrative values of a investment after growth and no costs applied at the end of the defined period |
||
Annual charges
Annual chargesThese are the annual costs based on an initial investment amount of assuming a net zero growth rate |
||
Effect of charges on return (%)
Effect of charges on return (%)These are the overall costs in percentage terms, based on an initial investment amount of assuming a growth rate |
||
Effect of charges on return (£)
Effect of charges on return (£)These are the overall costs in monetary value, based on an initial investment amount of assuming a growth rate |
||
What you might get back at with charges applied
What you might get back at with charges appliedThese are the illustrative values of a investment after growth and costs at the end of the defined period |
This illustration is not a forecast of future investment performance but merely a means to demonstrate the potential impact of costs and charges for an assumed return of . Whilst we make reasonable endeavours to ensure the accuracy of third party charges information, this is intended for illustrative purposes only and should not be relied upon. We do not warrant or represent that this information is accurate, complete or up to date, therefore we accept no responsibility or liability for its use
Performance
-
Chart Options
Select TimeframeFromToAdd comparator to chartNone
This fund's IA Sector (IA Specialist)
Another IA SectorSearch for Fund ComparatorAdd a FTSE Index
Current Comparators -
Cumulative Performance
1 month 3 months 6 months 1 year 3 years 5 years -5.10% -16.93% -16.55% -8.08% 16.15% -2.63%
Important Information
Headline performance can mask the true characteristics of a fund. Without fully understanding how a fund is managed, you may inadvertently become exposed to an undesirable level of risk to your capital. Some funds carry a dilution levy which reduces the number of units realised on any initial investment as an initial charge. If this fund carries such a levy it should be detailed in the Key Investor Information Document (KIID), which we must provide and you should read before investing.
The charts and performance data shown are supplied by an external data provider and may contain data that appears to precede the introduction of the clean unit class for this fund. In such cases, historical data has been synthesised at the entire discretion of that external provider as realistically as possible using historical data recorded against the previously available commission-paying version of the fund, adjusting for fees in the process.
Composition
View Fund Allocation by:
Important Documents
The documents listed below are the latest versions made available to our data provider by the fund management group, but may not necessarily reflect the applicable charges that would be levied should you purchase this fund via Charles Stanley Direct. You should treat the charges and other figures shown in the 'Overview' tab as accurate.
The Fact Sheet is supplied on a monthly basis by the management group and provides limited information on the fund. Past performance data and a review of how the fund has performed are commonly featured.
474,109 bytes PDF Document; last updated 31 Mar 2025
176,779 bytes PDF Document; last updated 07 Feb 2025
14,410,043 bytes PDF Document; last updated 30 Sep 2024
7,659,142 bytes PDF Document; last updated 31 Mar 2024
6,330,973 bytes PDF Document; last updated 07 Feb 2025
Management Team
Tazio Storni Lydia Haueter Marco Minonne
Tazio Storni
has managed this fund for 8 years and 11 months.
Tazio Storni joined Pictet Asset Management in October 2014 as a Senior Investment Manager in the Sector & Theme Funds team. He began his investment career in 2005 with UBS Global Asset Management, as a financial analyst covering Biotech, Medtech and Chemical companies. In 2010 he took over the responsibility for the UBS (Lux) Equity Health Care fund. Prior to joining Pictet Asset Management Tazio worked for Bellevue Asset Management as lead portfolio manager on the BB Biotech (Lux) Fund. He holds a Masters in Biology and a PhD in Immunology from the Eidgenössische Technishe Horchschule in Zurich (ETH). Tazio is a Chartered Financial Analyst (CFA) charterholder.
Manager Cumulative Performance v Peer Group
All funds managed by Tazio
Name of Security | Sole/Co | Managed Since |
---|---|---|
Pictet Health | Co | Feb 2018 |
Lydia Haueter
has managed this fund for 8 years and 11 months.
There is currently no biography information for Lydia Haueter .
Manager Cumulative Performance v Peer Group
All funds managed by Lydia
Name of Security | Sole/Co | Managed Since |
---|---|---|
Pictet Health | Co | Feb 2018 |
Marco Minonne
has managed this fund for 4 years and 10 months.
There is currently no biography information for Marco Minonne.
Manager Cumulative Performance v Peer Group